P-137 Efficacy and safety of atezolizumab plus bevacizumab in unresectable or advanced hepatocellular carcinoma: Real life data from 5 Swiss centers

نویسندگان

چکیده

The landscape of systemic therapies (ST) for advanced hepatocellular carcinoma (HCC) pts has evolved in recent years. So far, the IMbrave 150 study (NCT03434379; Finn RS NEJM 2020), with combination atezolizumab (atezo) + bevacizumab (bev), obtained best results regarding overall survival (OS) and progression free (PFS) treatment naïve pts. Still, data from real life scenario on safety efficacy this therapy is lacking. aim to report atezo bev outside RCT focusing measures. This a retrospective observational diagnosed HCC clinical practice January 2020 - November 2021. 83 were included. Median follow up 11 months(IQR 5-16). Male sex81%. age 68. Risk factors HCC; 29% alcohol, 26% viral, 14% nash, 11% alcohol+nash, alcohol+viral, 5% other. Cirrhotic yes 82%. BCLC B25%, C 75%. Prior ST 14%. Priot LRT 70%. Vascular invasion 40%. Number lesions 1 (14%), 2 (10%), 3 or more (55%), diffuse (14%). AFP≥400 (7%). ChildPugh class A5 40%A6 45% B7 4%B8 8%. EHS present 42%. At moment analysis, 18 had ongoing 41 alive. Pts received median 6 cycles (IQR 4-10). 49 (59%) presented some related adverse event (AE). Grade 3-4 AE 24 (29%). 5 seen Serious 19 (23%). most frequent being variceal bleeding, AKI-HRS, IO colitis liver failure. leading drug withdrawal occurred 20 (24%). 29 (35%) after bev. OS at 12 months was 75.2% (95%CI 64-83) 61.6% 49.4-71-7), respectively. PFS 42.7% (CI 95% 31.8-53) 24.8% 15-36), During pt achieved successful DS got OLT no recurrence 9 up. 4 have CR. In preliminary measures slightly beneath setting. These differences could be explained by inclusion previous ST, Child B patients flexible comorbidities criteria. Regarding total less than reported RCT. Atezo did not disappoint forecast made study, neither expected nor prognosis. individual cases, bringing curative approach.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

safety and efficacy of transcatheter arterial chemoemboliazation in the real-life management of unresectable hepatocellular carcinoma

results survival at 1-year, 2-years, 3-years and 5-years was 73.2%, 45.4%, 33.2% and 14.9% respectively. procedure-related mortality was 1.4%. multivariate analysis showed lesion diameter, child-pugh classification, alcohol abuse, tumor response and afp prior tace as independent prognostic factors of survival. patients diagnosed during surveillance had significantly better survival rates compar...

متن کامل

Safety and Efficacy of Transcatheter Arterial Chemoemboliazation in the Real-Life Management of Unresectable Hepatocellular Carcinoma

BACKGROUND Trans-arterial chemoembolization (TACE) is associated with better survival in BCLC-stage B patients with hepatocellular carcinoma (HCC) and Child-Pugh A whereas in Child-Pugh B there is no definite evidence of benefit. OBJECTIVES To assess the safety and efficacy of TACE during routine clinical practice in a consecutive Greek cohort of patients with unrespectable HCC. PATIENTS AN...

متن کامل

Efficacy and safety of azelaic acid 20% plus hydroquinone 5% in the management of melasma

Background: Melasma is a brown or grayish brown symmetrical facial hyperpigmentation.A number of medicamens can be used for the treatment of this condition. For better results in treating melasma, combination therapy is preferred. The aim of this study was to determine the clinical efficacy and adverse effects of azelaic acid 20% plus hydroquinone 5% versus hydroquinone 5% alone in the manageme...

متن کامل

Efficacy and Safety of Intensity-Modulated Radiotherapy Following Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma

Three-dimensional conformal radiotherapy in combination with transarterial chemoembolization (TACE) has been beneficial in patients with unresectable hepatocellular carcinoma (HCC). There have been few clinical reports on the use of intensity-modulated radiotherapy (IMRT) in combination with TACE for these patients. The purpose of this study was to assess the efficacy and toxicity of IMRT follo...

متن کامل

Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials

BACKGROUND Hepatocellular carcinoma (HCC) is a common cancer associated with a poor prognosis. Bevacizumab is a monoclonal antibody that binds vascular endothelial growth factor, a mediator of tumor angiogenesis. Bevacizumab is currently under investigation as treatment for HCC. We performed a systematic review of the efficacy and safety of bevacizumab for the treatment of advanced HCC. METHO...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Annals of Oncology

سال: 2022

ISSN: ['0923-7534', '1569-8041']

DOI: https://doi.org/10.1016/j.annonc.2022.04.227